The benefit of talazoparib in BRCA1/2-mutated patients with human epidermal receptor-2 (HER2) negative advanced breast cancer (ABC) has been demonstrated in several phase I/II clinical trials (4–6). This evidence concerns the gene BRCA1 and breast cancer.